TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25424715

Group type: EXPERIMENTAL
Intervention: GRM-derived SNP-based heritability estimates for GGT
Number of subjects: 5421

Group type: EXPERIMENTAL
Intervention: GRM-derived SNP-based heritability estimates for AST
Number of subjects: 5421

Group type: EXPERIMENTAL
Intervention: GRM-derived SNP-based heritability estimates for ALT
Number of subjects: 5421

Group type: EXPERIMENTAL
Intervention: DE method for all liver enzymes
Number of subjects: 5421

Group type: EXPERIMENTAL
Intervention: DE method applied to meta-analysis results for GGT
Number of subjects: 5421

Group type: EXPERIMENTAL
Intervention: DE method applied to meta-analysis results for ALT
Number of subjects: 5421
Study: 23403276

Group type: EXPERIMENTAL
Intervention: Loss-framed incentives ($75 loss per day for smoking, initial endowment=$375)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gain-framed incentives ($75 gain per day for abstinence)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loss-framed incentives
Number of subjects: 0
Study: 21861971

Group type: EXPERIMENTAL
Intervention: 20% reduction in retinal thickness
Number of subjects: 101

Group type: COMPARATOR
Intervention: No 20% reduction in retinal thickness
Number of subjects: 101
Study: 18542850

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGBP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 17384434

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 984
Study: 15170977

Group type: EXPERIMENTAL
Intervention: FOLFOX 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFL regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5‐FU and leucovorin (FL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of IFL and bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: de Gramont regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: CPT‐11 and oxaliplatin (IROX)
Number of subjects: 0
Study: 12752559

Group type: EXPERIMENTAL
Intervention: Non-hypotensive haemorrhage (5.6 +/- 1.2 ml kg-1 body weight)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Non-hypotensive haemorrhage
Number of subjects: 30
Study: 9916067

Group type: EXPERIMENTAL
Intervention: Liposomal antigen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antigen only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 7675920

Group type: EXPERIMENTAL
Intervention: Stressful laboratory task (N = 40)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rest condition (N = 30)
Number of subjects: 70
Study: 2292547

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intra-peritoneal vancomycin/gentamicin
Number of subjects: 51
Study: 7292264

Group type: EXPERIMENTAL
Intervention: Prophylactic oophorectomy
Number of subjects: 359

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 359
Study: 30044438

Group type: EXPERIMENTAL
Intervention: Almond snack (56.7 g/day; 364 kcal; n = 38)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Graham cracker control (77.5 g/day; 338 kcal/d; n = 35)
Number of subjects: 73
Study: 26922457

Group type: EXPERIMENTAL
Intervention: Redesigned Rx labels (n = 90)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Redesigned Rx labels (n = 48) after educational intervention
Number of subjects: 118

Group type: COMPARATOR
Intervention: Current Rx labels (n = 16) after educational intervention
Number of subjects: 118

Group type: COMPARATOR
Intervention: Current Rx labels (n = 28)
Number of subjects: 118
Study: 24907871

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 80

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 80
Study: 22393219

Group type: EXPERIMENTAL
Intervention: MFG-adherence
Number of subjects: 174

Group type: COMPARATOR
Intervention: MFG-standard
Number of subjects: 174

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 174
Study: 19889469

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment (stepwise implementation of behavior modification, pharmacological therapy targeting hyperglycaemia, hypertension, dyslipidaemia, and proteinuria)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 600
Study: 19079390

Group type: EXPERIMENTAL
Intervention: Primary posterior capsulotomy (PPC)
Number of subjects: 114

Group type: COMPARATOR
Intervention: No primary posterior capsulotomy (NPPC)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both PPC and NPPC
Number of subjects: 114
Study: 16268465

Group type: EXPERIMENTAL
Intervention: Femoral CVL
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Subclavian CVL
Number of subjects: 158

Group type: COMPARATOR
Intervention: Brachial CVL
Number of subjects: 158

Group type: COMPARATOR
Intervention: Jugular CVL
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: CVL type (peripherally inserted central catheters, untunneled CVL, tunneled exteriorized CVL, subcutaneous ports)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: CVL size (CVL diameter, number of CVL lumen)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Duration of CVL placement (0-5 days, 6-20 days, 21-35 days, 36-50 days)
Number of subjects: 158
Study: 12297918

Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1), n = 18
Number of subjects: 44

Group type: COMPARATOR
Intervention: No PGE1 treatment (PGE1(-) group), n = 26
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Three-field lymph node dissection and reconstruction of the retrosternal route, n = 21
Number of subjects: 44

Group type: COMPARATOR
Intervention: Two-field lymph-node dissection and reconstruction of the posterior mediastinal route, n = 23
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Leakage(+) group, n = 5
Number of subjects: 44

Group type: COMPARATOR
Intervention: Leakage(?) group, n = 39
Number of subjects: 44
Study: 11074998

Group type: EXPERIMENTAL
Intervention: Graftskin plus compression therapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Compression therapy alone (active control)
Number of subjects: 240
Study: 8777102

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (240 kJ h‐1, infused over 1‐2 h before anaesthesia)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 24
Study: 2000818

Group type: EXPERIMENTAL
Intervention: 50 mg beta-carotene/d orally
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 6653137

Group type: EXPERIMENTAL
Intervention: Pholcolix
Number of subjects: 217

Group type: COMPARATOR
Intervention: Actifed Compound
Number of subjects: 217
Study: 31651407

Group type: EXPERIMENTAL
Intervention: Food-coaching smartphone app (Glycoleap, Holmusk, Singapore) for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard pregnancy dietary orientation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Food-coaching smartphone app (Glycoleap, Holmusk, Singapore)
Number of subjects: 30
Study: 29142294

Group type: EXPERIMENTAL
Intervention: GnRH 10 μg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: GnRH 50 μg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: GnRH 100 μg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: GnRH (all doses)
Number of subjects: 67
Study: 27084861

Group type: EXPERIMENTAL
Intervention: Coconut oil pulling (10 ml for 10 minutes)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash (5 ml for 1 minute)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distilled water (5 ml for 1 minute)
Number of subjects: 60
Study: 25458229

Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study: 23006479

Group type: EXPERIMENTAL
Intervention: High-dose ascorbic acid intravenously before exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-intensity (0.5 kg) rhythmic plantar flexion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrically evoked exercise
Number of subjects: 0
Study: 20339913

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day
Number of subjects: 700

Group type: COMPARATOR
Intervention: Capecitabine 1,250 mg/m2 (1,000 mg/m2 in patients >65 years) BID on days 1-14 q3w
Number of subjects: 700
Study: 17276006

Group type: EXPERIMENTAL
Intervention: 15-point transition question (TQ2)
Number of subjects: 233

Group type: COMPARATOR
Intervention: 7-point transition question (TQ1)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Retrospective transition questions (TQ1 and TQ2)
Number of subjects: 233
Study: 15907777

Group type: EXPERIMENTAL
Intervention: Active dose of alcohol (0.65 g/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11821453

Group type: EXPERIMENTAL
Intervention: Trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Trastuzumab 8 mg/kg loading dose, followed by 4 mg/kg weekly
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Trastuzumab (both dosages)
Number of subjects: 114
Study: 10351855

Group type: EXPERIMENTAL
Intervention: STARS for Families Program (alcohol reduction program with standardized health consultations and mailed follow‐up information)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Minimum information (control group)
Number of subjects: 650
Study: 7717559

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.8‐1.2%)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg bolus plus infusion of 150 micrograms.kg‐1.min‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline anesthesia (thiopental, alfentanil, nitrous oxide, and pancuronium)
Number of subjects: 20
Study: 8455371

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) with regenerated cellulose
Number of subjects: 12

Group type: COMPARATOR
Intervention: PBMC re-entering the dialyzer from systemic circulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: HD using less complement-activating membranes (hemophan, polysulfone, polyamide, polyacrylonitrile)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Monoclonal antibody against human C5a
Number of subjects: 12
Study: 3510384

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (125 mg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 97
Study: 29326184

Group type: EXPERIMENTAL
Intervention: Health-E You app
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1400
Study: 26506890

Group type: EXPERIMENTAL
Intervention: Personalized treatment strategy based on patient information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot study data
Number of subjects: 0
Study: 25676405

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (PVB) before general anesthesia in group GP
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia only in group G
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (GP and G)
Number of subjects: 40
Study: 23358780

Group type: EXPERIMENTAL
Intervention: Training program for daycare teachers
Number of subjects: 96

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 96
Study: 20731585

Group type: EXPERIMENTAL
Intervention: EMLA cream applied during scaling
Number of subjects: 40

Group type: COMPARATOR
Intervention: No EMLA cream applied during scaling
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler used
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gracey curet used
Number of subjects: 40
Study: 19902797

Group type: EXPERIMENTAL
Intervention: Combined supplement of 40 mg of zinc as zinc gluconate and 40 mg of iron as ferrous sulphate
Number of subjects: 600

Group type: COMPARATOR
Intervention: 40 mg of elemental iron as ferrous sulphate
Number of subjects: 600
Study: 16517274

Group type: EXPERIMENTAL
Intervention: Pneumococcal protein D conjugate
Number of subjects: 4968

Group type: COMPARATOR
Intervention: Hepatitis A vaccine (Control)
Number of subjects: 4968
Study: 15297105

Group type: EXPERIMENTAL
Intervention: Virgin olive oil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sunflower oil
Number of subjects: 20
Study: 10664922

Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg bid, escalated to 30 mg bid, then to 40 mg bid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9881555

Group type: EXPERIMENTAL
Intervention: Combined phacoemulsification and trabeculectomy (phaco-trab)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional phacoemulsification (phaco)
Number of subjects: 20
Study: 7817443

Group type: EXPERIMENTAL
Intervention: Mitomycin C (short-term intensive weekly instillation)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Mitomycin C (3-year protocol)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Adriamycin regimen
Number of subjects: 333

Group type: COMPARATOR
Intervention: Combination of short-term and 3-year protocols
Number of subjects: 333
Study: 3041327

Group type: EXPERIMENTAL
Intervention: Morphine (10 mg i.m.)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caerulein (5 micrograms i.m.)
Number of subjects: 36
Study: 30364350

Group type: EXPERIMENTAL
Intervention: Metformin treatment (n = 7)
Number of subjects: 29
Study: 27661192

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (20 IU)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (saline nasal spray)
Number of subjects: 17
Study: 24398722

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A-tDCS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (S-tDCS)
Number of subjects: 16
Study: 22738803

Group type: EXPERIMENTAL
Intervention: Safety closed IV catheter system (BD Pegasus*)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Non-safety device (BD Intima II)
Number of subjects: 257
Study: 21081801

Group type: EXPERIMENTAL
Intervention: L-tryptophan 500 mg twice daily and Essentiale forte 3 times a day for 4 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg twice a day and Essentiale forte 3 times a day for 4 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Essentiale forte with placebo 3 times a day for 4 weeks
Number of subjects: 45
Study: 18759317

Group type: EXPERIMENTAL
Intervention: Specialized rheumatology nurse (SRN) group, n = 97
Number of subjects: 193

Group type: COMPARATOR
Intervention: Rheumatologist (RMT) group, n = 96
Number of subjects: 193
Study: 16198932

Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.8 g/kg/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual-protein diet
Number of subjects: 63
Study: 12456423

Group type: COMPARATOR
Intervention: Nalbuphine 4 mg (Group N)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Droperidol 0.625 mg plus nalbuphine 4 mg (Group ND)
Number of subjects: 124
Study: 9550507

Group type: EXPERIMENTAL
Intervention: Increased oxygen extraction fraction (OEF) in patients with prior ischemic symptoms
Number of subjects: 117

Group type: COMPARATOR
Intervention: Normal oxygen extraction fraction (OEF) in asymptomatic patients
Number of subjects: 117
Study: 2569323

Group type: EXPERIMENTAL
Intervention: Prescription Information Leaflets (PILs) distributed by pharmacists or general practitioners
Number of subjects: 719

Group type: COMPARATOR
Intervention: No Prescription Information Leaflets (Control)
Number of subjects: 719
Study: 770552

Group type: EXPERIMENTAL
Intervention: Aspirin challenge
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Double-blind protocol
Number of subjects: 50
Study: 29957680

Group type: EXPERIMENTAL
Intervention: Intervention group received a brochure and an outreach telephone call.
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group received no active outreach.
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Telephone outreach for intervention group.
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Intervention group ratings of communication and support for speaking up.
Number of subjects: 115
Study: 31132980

Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarian diet rich in omega-3 (n=18)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lacto-ovo-vegetarian diet rich in EVO (n=22)
Number of subjects: 54
Study: 28736309

Group type: EXPERIMENTAL
Intervention: Training program aimed at improving cognitive control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training program
Number of subjects: 0
Study: 25803783

Group type: EXPERIMENTAL
Intervention: BCAA and arginine supplementation (0.17 g/kg BCAA and 0.04 g/kg arginine)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PB trial)
Number of subjects: 22
Study: 24063176

Group type: EXPERIMENTAL
Intervention: PCL retaining group (group A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: PCL substituting group (group B)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 38
Study: 21327794

Group type: EXPERIMENTAL
Intervention: L + A (leg exercises before elbow flexor training)
Number of subjects: 9

Group type: COMPARATOR
Intervention: A (arm training without prior leg exercises)
Number of subjects: 9
Study: 19739491

Group type: EXPERIMENTAL
Intervention: Enriched formula (Kcal: 75/100 ml, proteins: 2 g/100 ml)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard formula (Kcal: 67/100 ml, proteins: 1.4 g/100 ml)
Number of subjects: 27
Study: 17766511

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 194
Study: 15037328

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg once daily
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 200 mg once daily
Number of subjects: 1123

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 1123
Study: 11319653

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/day) with a low-fat low-energy individualized diet (600 kcal/day deficit)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/day)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study: 9874862

Group type: EXPERIMENTAL
Intervention: Sufentanil (10 micrograms) added to 12.5 mg of 0.5% bupivacaine
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0.5% bupivacaine alone (Control group)
Number of subjects: 41
Study: 7857761

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (enalapril, captopril)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardiac glycosides
Number of subjects: 0
Study: 3168937

Group type: EXPERIMENTAL
Intervention: Iopamidol (Niopam)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Urografin (meglumine diatrizoate)
Number of subjects: 85
Study: 348532

Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diflunisal 125 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diflunisal 250 mg
Number of subjects: 0
Study: 31668721

Group type: COMPARATOR
Intervention: 1.5 L of Sterofundin ISO (Reference arm A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.5 L of 4% Gelaspan® (Isoeffective arm B)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.5 L of 4% Gelaspan® and 1 L of Sterofundin ISO (Isovolumetric arm C)
Number of subjects: 12
Study: 31163434

Group type: EXPERIMENTAL
Intervention: Uric acid 1,000 mg
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study: 29019886

Group type: EXPERIMENTAL
Intervention: ERAS group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 25845864

Group type: EXPERIMENTAL
Intervention: delafloxacin 300 mg i.v. (therapeutic)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: delafloxacin 900 mg i.v. (supratherapeutic)
Number of subjects: 52

Group type: COMPARATOR
Intervention: moxifloxacin 400 mg orally (positive control)
Number of subjects: 52

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 52
Study: 24158584

Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Monitored group (no further treatment)
Number of subjects: 62
Study: 22264450

Group type: EXPERIMENTAL
Intervention: Palatinose™
Number of subjects: 20

Group type: COMPARATOR
Intervention: glucose syrup/sucrose (glc/suc)
Number of subjects: 20
Study: 19932541

Group type: EXPERIMENTAL
Intervention: Lovastatin, 20 mg/d
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 17088036

Group type: EXPERIMENTAL
Intervention: Hydrogel containing 5% of a crude extract standardized in its tannin concentration (1.8%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrogel without addition of the extract (Control)
Number of subjects: 0
Study: 16305977

Group type: EXPERIMENTAL
Intervention: benazepril 20 mg/day
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: benazepril 10 mg/day plus valsartan 80 mg/day
Number of subjects: 203

Group type: COMPARATOR
Intervention: valsartan 160 mg/day
Number of subjects: 203
Study: 12193905

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 23
Study: 9862607

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nondepressed community sample)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with full symptomatic response (remission)
Number of subjects: 0
Study: 8700610

Group type: EXPERIMENTAL
Intervention: Cotton ball method
Number of subjects: 30

Group type: COMPARATOR
Intervention: Preemie Pampers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Newborn Pampers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cotton ball and catheterization
Number of subjects: 30
Study: 2496173

Group type: EXPERIMENTAL
Intervention: Zidovudine (250 mg every 4 hours)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ribavirin (800 mg or 600 mg daily)
Number of subjects: 29